Yunfeng Capital

Yunfeng Capital is a Shanghai-headquartered private equity firm co-founded by Jack Ma, deploying substantial capital into mature healthcare services, digital platforms, and consumer technology enterprises. The firm operates as a growth-stage and PE investor with the scale and institutional reach that comes from its founding lineage and the breadth of its LP base.

The healthcare thesis spans biotech, digital health, and care delivery and tech-enabled services, with AI focus across those categories. Yunfeng Capital invests where there is meaningful commercial traction and clear paths to platform-scale revenue, often in healthcare services and digital platforms that can leverage Chinese consumer scale. The firm’s PE heritage means it indexes more heavily on operational improvement and value creation than on early venture risk.

The firm writes $25M-plus checks across Series B, Series C, and Growth, which is the late-stage and PE coverage that defines its mandate. Geographic focus is China, with selective international participation when portfolio companies expand globally, and the firm’s capital depth means it can lead or co-lead substantial rounds. Founders raising sub-$25M rounds or operating at venture-stage risk should look elsewhere.

The team operates within the broader Yunfeng franchise and benefits from access to institutional networks, operational expertise, and the relationships that flow from the firm’s founding lineage. Specific partner names are not provided in the source data, and founders should engage through Yunfeng Capital’s main channels and expect institutional engagement processes rather than open inbound venture pitches.

The approach is growth-PE with an operational tilt. Yunfeng Capital expects clear unit economics, credible scale paths, and management teams capable of operating through the governance demands of a large institutional investor. The firm is a strong fit for late-stage Chinese healthcare and digital platform companies that benefit from substantial growth capital and operational support. Founders at venture-stage risk or those without meaningful China commercial exposure will be a poor structural fit.